These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 34140350)

  • 1. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
    Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
    Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.
    Carroll T; Fox D; van Doremalen N; Ball E; Morris MK; Sotomayor-Gonzalez A; Servellita V; Rustagi A; Yinda CK; Fritts L; Port JR; Ma ZM; Holbrook MG; Schulz J; Blish CA; Hanson C; Chiu CY; Munster V; Stanley S; Miller CJ
    PLoS Pathog; 2022 Feb; 18(2):e1009914. PubMed ID: 35143587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
    Sasaki M; Toba S; Itakura Y; Chambaro HM; Kishimoto M; Tabata K; Intaruck K; Uemura K; Sanaki T; Sato A; Hall WW; Orba Y; Sawa H
    mBio; 2021 Aug; 12(4):e0141521. PubMed ID: 34425707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta.
    Ulrich L; Halwe NJ; Taddeo A; Ebert N; Schön J; Devisme C; Trüeb BS; Hoffmann B; Wider M; Fan X; Bekliz M; Essaidi-Laziosi M; Schmidt ML; Niemeyer D; Corman VM; Kraft A; Godel A; Laloli L; Kelly JN; Calderon BM; Breithaupt A; Wylezich C; Berenguer Veiga I; Gultom M; Osman S; Zhou B; Adea K; Meyer B; Eberhardt CS; Thomann L; Gsell M; Labroussaa F; Jores J; Summerfield A; Drosten C; Eckerle IA; Wentworth DE; Dijkman R; Hoffmann D; Thiel V; Beer M; Benarafa C
    Nature; 2022 Feb; 602(7896):307-313. PubMed ID: 34937050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.
    Stauft CB; Lien CZ; Selvaraj P; Liu S; Wang TT
    Virology; 2021 Apr; 556():96-100. PubMed ID: 33556653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.
    Carroll T; Fox D; van Doremalen N; Ball E; Morris MK; Sotomayor-Gonzalez A; Servellita V; Rustagi A; Yinda CK; Fritts L; Port JR; Ma ZM; Holbrook M; Schulz J; Blish CA; Hanson C; Chiu CY; Munster V; Stanley S; Miller CJ
    bioRxiv; 2021 Aug; ():. PubMed ID: 34462750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
    Radvak P; Kwon HJ; Kosikova M; Ortega-Rodriguez U; Xiang R; Phue JN; Shen RF; Rozzelle J; Kapoor N; Rabara T; Fairman J; Xie H
    Nat Commun; 2021 Nov; 12(1):6559. PubMed ID: 34772941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
    O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
    EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Chiba S; Halfmann PJ; Iida S; Hirata Y; Sato Y; Kuroda M; Armbrust T; Spyra S; Suzuki T; Kawaoka Y
    Vaccine; 2023 Sep; 41(41):6025-6035. PubMed ID: 37635002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.
    Imai M; Iwatsuki-Horimoto K; Hatta M; Loeber S; Halfmann PJ; Nakajima N; Watanabe T; Ujie M; Takahashi K; Ito M; Yamada S; Fan S; Chiba S; Kuroda M; Guan L; Takada K; Armbrust T; Balogh A; Furusawa Y; Okuda M; Ueki H; Yasuhara A; Sakai-Tagawa Y; Lopes TJS; Kiso M; Yamayoshi S; Kinoshita N; Ohmagari N; Hattori SI; Takeda M; Mitsuya H; Krammer F; Suzuki T; Kawaoka Y
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16587-16595. PubMed ID: 32571934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters.
    Plunkard J; Mulka K; Zhou R; Tarwater P; Zhong W; Lowman M; Wong A; Pekosz A; Villano J
    mBio; 2023 Apr; 14(2):e0007823. PubMed ID: 37036339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters.
    Halfmann PJ; Kuroda M; Maemura T; Chiba S; Armbrust T; Wright R; Balaram A; Florek KR; Bateman AC; Kawaoka Y
    Cell Rep; 2022 Apr; 39(3):110688. PubMed ID: 35421378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Faizuloev E; Gracheva A; Korchevaya E; Smirnova D; Samoilikov R; Pankratov A; Trunova G; Khokhlova V; Ammour Y; Petrusha O; Poromov A; Leneva I; Svitich O; Zverev V
    Vaccine; 2023 Jan; 41(4):892-902. PubMed ID: 36528447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
    Saito A; Irie T; Suzuki R; Maemura T; Nasser H; Uriu K; Kosugi Y; Shirakawa K; Sadamasu K; Kimura I; Ito J; Wu J; Iwatsuki-Horimoto K; Ito M; Yamayoshi S; Loeber S; Tsuda M; Wang L; Ozono S; Butlertanaka EP; Tanaka YL; Shimizu R; Shimizu K; Yoshimatsu K; Kawabata R; Sakaguchi T; Tokunaga K; Yoshida I; Asakura H; Nagashima M; Kazuma Y; Nomura R; Horisawa Y; Yoshimura K; Takaori-Kondo A; Imai M; ; Tanaka S; Nakagawa S; Ikeda T; Fukuhara T; Kawaoka Y; Sato K
    Nature; 2022 Feb; 602(7896):300-306. PubMed ID: 34823256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.